UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 228

Sortiert nach

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of oncology, 2018-07, Vol.29 (7), p.1541-1547

2018

Volltextzugriff (PDF)

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

European journal of cancer (1990), 2011-01, Vol.47 (1), p.8-32

2011

Volltextzugriff (PDF)

The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer

Human reproduction (Oxford), 2006-10, Vol.21 (10), p.2583-2592

2006

Volltextzugriff (PDF)

Carbon dioxide and energy fluxes from a boreal mixedwood forest ecosystem in Ontario, Canada

Agricultural and forest meteorology, 2006-11, Vol.140 (1), p.79-96

2006

Volltextzugriff (PDF)

Prevalence of tricuspid regurgitation and pericardial effusions following pacemaker and defibrillator lead extraction

International journal of cardiology, 2010-12, Vol.145 (3), p.593-594

2010

Volltextzugriff (PDF)

489 Outcomes of Axillary Dissection Following a Positive Sentinel Node or Node Sample – Retrospective Study of Two Years Practise in a Large Breast Unit

European journal of cancer (1990), 2012-03, Vol.48, p.S189-S189

2012

Volltextzugriff (PDF)

1809 Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer usIng Multi-parameter Analysis) prelim study

European journal of cancer (1990), 2015-09, Vol.51, p.S268-S268

2015

Volltextzugriff (PDF)

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (1), p.9-20

2022

Volltextzugriff (PDF)

Her2 positive breast cancer from optimal diagnosis to optimal treatment

European journal of cancer supplements, 2008, Vol.6 (7), p.39-40

Cameron, D.A

2008

Volltextzugriff (PDF)

Cost-effectiveness of first-line ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2

European journal of cancer (1990), 2022-11, Vol.175, p.S67

2022

Volltextzugriff (PDF)

Randomised controlled trial of breast conserving therapy: 30 year analysis of the Scottish breast conservation trial

European journal of cancer (1990), 2022-11, Vol.175, p.S1-S2

2022

Volltextzugriff (PDF)

Stopping Tamoxifen after 5 Years of Therapy for Early Breast Cancer: Does it Alter Quality of Life?

Clinical oncology (Royal College of Radiologists (Great Britain)), 2011-11, Vol.23 (9), p.652-652

2011

Volltextzugriff (PDF)

Herceptin – from bedside to bench to clinic?

European journal of cancer supplements, 2007-09, Vol.5 (5), p.372-374

Cameron, D.A

2007

Volltextzugriff (PDF)

Physical impairments related to kinetic energy during sit-to-stand and curb-climbing following stroke

Clinical biomechanics (Bristol), 2003-05, Vol.18 (4), p.332-340

2003

Volltextzugriff (PDF)

307P Identifying new biological subgroups of triple-negative breast cancer using next-generation integrative clustering pipeline

Annals of oncology, 2023-10, Vol.34, p.S306-S307

2023

Volltextzugriff (PDF)

309P Machine learning-based characterization of tumor-immune microenvironment at a spatial and multiplexed resolution in early breast cancer: A sub-study of the EORTC 10994/BIG 1-00 randomized phase III trial with long-term follow-up

Annals of oncology, 2023-10, Vol.34, p.S307-S308

2023

Volltextzugriff (PDF)

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of oncology, 2019-11, Vol.30 (11), p.1842-1842

2019

Volltextzugriff (PDF)

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

European journal of cancer (1990), 2006-10, Vol.42 (15), p.2433-2453

2006

Volltextzugriff (PDF)

217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

Annals of oncology, 2022-09, Vol.33, p.S632-S633

2022

Volltextzugriff (PDF)

Occurrence of peritoneal carcinomatosis in patients with rectal cancer undergoing staging pelvic MRI: clinical observations

European radiology, 2022-08, Vol.32 (8), p.5097-5105

2022

Volltextzugriff (PDF)

Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy

Journal of steroid biochemistry and molecular biology, 2001-12, Vol.79 (1), p.103-107

2001

Volltextzugriff (PDF)

356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study

Annals of oncology, 2023-10, Vol.34, p.S325-S326

2023

Volltextzugriff (PDF)

376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

Annals of oncology, 2023-10, Vol.34, p.S334-S335

2023

Volltextzugriff (PDF)

Attenuation of Smooth Muscle Cell Phenotypic Switching by Angiotensin 1-7 Protects against Thoracic Aortic Aneurysm

International journal of molecular sciences, 2022-12, Vol.23 (24), p.15566

2022

Volltextzugriff (PDF)

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial

Annals of oncology, 2017-08, Vol.28 (8), p.1832-1835

2017

Volltextzugriff (PDF)

1 – 25 von 228

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(207)
Mit Volltextzugriff
(193)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(115)
Life Sciences & Biomedicine
(80)
Female
(44)
Animals
(39)
Humans
(39)
Physical Sciences
(35)
Biological And Medical Sciences
(34)
Medical Sciences
(27)
Oncology
(25)
Physics
(23)
Male
(22)
Breast Neoplasms - Drug Therapy
(19)
Middle Aged
(18)
Veterinary Sciences
(17)
Pharmacology. Drug Treatments
(15)
Aged
(13)
Antineoplastic Agents
(13)
Breast Cancer
(13)
Chemotherapy
(13)
Hematology, Oncology And Palliative Medicine
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

European Journal Of Cancer
(14)
Nuclear Physics. A
(14)
Physics Letters. B
(13)
Annals Of Oncology
(12)
Australian Veterinary Journal
(11)
Breast
(8)
International Journal Of Radiation Oncology, Biology, Physics
(7)
Pathology
(7)
Theriogenology
(5)
Nuclear Physics A
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer

Carbon dioxide and energy fluxes from a boreal mixedwood forest ecosystem in Ontario, Canada

Prevalence of tricuspid regurgitation and pericardial effusions following pacemaker and defibrillator lead extraction

489 Outcomes of Axillary Dissection Following a Positive Sentinel Node or Node Sample – Retrospective Study of Two Years Practise in a Large Breast Unit

1809 Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer usIng Multi-parameter Analysis) prelim study

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Her2 positive breast cancer from optimal diagnosis to optimal treatment

Cost-effectiveness of first-line ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2

Randomised controlled trial of breast conserving therapy: 30 year analysis of the Scottish breast conservation trial

Stopping Tamoxifen after 5 Years of Therapy for Early Breast Cancer: Does it Alter Quality of Life?

Herceptin – from bedside to bench to clinic?

Physical impairments related to kinetic energy during sit-to-stand and curb-climbing following stroke

307P Identifying new biological subgroups of triple-negative breast cancer using next-generation integrative clustering pipeline

309P Machine learning-based characterization of tumor-immune microenvironment at a spatial and multiplexed resolution in early breast cancer: A sub-study of the EORTC 10994/BIG 1-00 randomized phase III trial with long-term follow-up

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

Occurrence of peritoneal carcinomatosis in patients with rectal cancer undergoing staging pelvic MRI: clinical observations

Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy

356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study

376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

Attenuation of Smooth Muscle Cell Phenotypic Switching by Angiotensin 1-7 Protects against Thoracic Aortic Aneurysm

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial

Suchergebnisse filtern